Efficacy of rimonabant in obese patients with binge eating disorder

  • Pataky Z
  • Gasteyger C
  • Ziegler O
 et al. 
  • 34


    Mendeley users who have this article in their library.
  • 21


    Citations of this article.


In obesity, a dysregulation of the endocannabinoid system has been shown. The endocannabinoid receptor blockage by rimonabant demonstrated interesting metabolic effects. However, the role of rimonabant in weight loss of patients with binge eating disorder has not been investigated. Thus, our aim was to evaluate the effects of rimonabant on body weight in obese patients with binge eating disorders. This multicenter, randomized, double-blind, placebo-controlled study included 289 obese subjects (age 18-70 years, body mass index 30-45 kg/m(2)) with binge eating disorders. Subjects were randomized (1:1) to receive rimonabant 20 mg/day or placebo for 6 months. In total, 289 participants (age: 43.2±10.5 yrs, 91% of women) were randomized. The completer rate was similar (71%) in both treatment and placebo groups. Participants treated with rimonabant lost 4.7±5.2% of their initial body weight, vs. 0.4±4.5% in the placebo group (difference between both groups: 4.4±0.6 kg, p

Author-supplied keywords

  • binge eating disorder
  • endocannabinoid system
  • obesity
  • rimonabant

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Z. Pataky

  • C. Gasteyger

  • O. Ziegler

  • A. Rissanen

  • C. Hanotin

  • A. Golay

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free